THX Pharma
PAR: ALTHX.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mathieu Charvériat
- Employees
- 12
- Headquarters
- Lyon, France
- IPO year
- 2017
- Market cap
- €31.3M
- Website
- https://www.theranexus.com
Loading ALTHX…
Loading profile data…Frequently asked questions about ALTHX
What does THX Pharma (ALTHX.PA) do?
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's diseas...
Where does ALTHX.PA trade?
THX Pharma (ALTHX.PA) trades on the Euronext Paris.
What sector is ALTHX.PA in?
THX Pharma (ALTHX.PA) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of THX Pharma?
Mathieu Charvériat is the chief executive officer of THX Pharma (ALTHX.PA).
Where is THX Pharma headquartered?
THX Pharma is headquartered in France.
Does ALTHX.PA pay a dividend?
THX Pharma (ALTHX.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALTHX.PA go public?
THX Pharma (ALTHX.PA) completed its initial public offering in 2017.